We provide you with 20 years of free, institutional-grade data for NKTX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of NKTX. Explore the full financial landscape of NKTX stock.
| Reported Date | CIK | Ticker | Type |
|---|
Nkarta, Inc(NASDAQ:NKTX) 
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific p...
Website: http://www.nkartatx.com
Founded: 2015
CEO: Paul J. Hastings
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about NKTX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.